MedTrace Logo

Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock

NCT04608448 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-07-19

Study results available
· View outcomes & findings →

Summary

Topical Rapamycin ointment will be applied to participant forearms to test whether epigenetic changes in the skin are elicited.

Conditions

  • Aging
  • Epigenetics
  • Inflammatory Mediators

Interventions

DRUG

Rapamycin Topical Ointment

8% topical rapamycin ointment

OTHER

Placebo

Petrolatum ointment containing no active ingredient

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Ellen Kraig, PhD · University of Texas Health at San Antonio

  • Dean L Kellogg, Jr., MD, PhD · University of Texas Health at San Antonio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-28
Primary Completion
2022-04-15
Completion
2022-04-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04608448 on ClinicalTrials.gov